SAGE Therapeutics (SAGE) Misses Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to SAGE Therapeutics (SAGE) Misses Q3 EPS by 10c

SAGE Therapeutics Reports Third Quarter 2014 Results

November 11, 2014 6:30 AM EST

CAMBRIDGE, Mass., Nov. 11, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today reported pipeline updates and reported business and financial results for the quarter ended Sept. 30, 2014.

"So far this year, we have made great progress towards our mission to improve the lives of patients living with rare and severe CNS disorders," said Jeff Jonas, M.D., chief executive officer of SAGE. "Financial results were in line with expectations, and we recently announced that we met both the primary... More